A preliminary report indicates that in the postprandial state lipemia diminishes, and endothelial dysfunction improves in non-diabetic subjects [111]
These metabolic disorders must be clinically followed up and continuously treated
For example, researchers from a 2016 review of data on the gut-brain axis and BPC-157 explain that the peptide could maintain gastrointestinal mucosa, modulate serotonergic and dopaminergic systems, regenerate peripheral nerves, protect certain neurons, counteract various types of lesions, promote wound healing, and more.7 Some of these possible benefits are due to BPC-157s promotion of the cell migration of vascular endothelial cells.24 This means that the peptide can encourage the formation of new blood vessels (also known as angiogenesis)
Employer FAQs on the Rise of GLP-1 Drugs for Weight Loss and the Workplace Impact The rise of prescription medications used for weight loss has reshaped conversations about employer-sponsored health benefits and raised many new questions for employers
A July 2024 Harvard study found diabetes patients prescribed semaglutide were over four times likely to develop NAION, while those prescribed it for weight loss were over seven times likely to develop this condition
